LENZING AG financials
LENZING AG
Country: AT Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
529900BKFJBI0QRDJH63 ISIN: AT0000644505 Financial statements
(EUR, as reported — unscaled; 113 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €2.60B | €2.66B |
| Cost of sales | €2.26B | €2.16B |
| Gross profit | €338.4M | €508.1M |
| Other income | €133.6M | €61.8M |
| Distribution costs | €280.9M | €300.5M |
| Administrative expenses | €126.3M | €146.7M |
| Operating profit (EBIT) | €17.6M | €88.5M |
| Net finance income / (cost) | -€140.1M | -€130.5M |
| Finance costs | €136.0M | €164.3M |
| Profit before tax | -€122.5M | -€42.0M |
| Income tax expense | €12.7M | €96.3M |
| Profit for the year | -€135.2M | -€138.3M |
| — attributable to NCI | €36.8M | -€10.4M |
| Total comprehensive income | -€247.4M | -€117.6M |
| Per share | ||
| Diluted EPS | €-5.45 | €-4.06 |
| Free cash flow / share | €11.23 | €7.08 |
| Cash flow statement | ||
| Net cash from operating activities | €419.7M | €395.0M |
| Net cash from investing activities | -€146.9M | -€152.1M |
| Net cash from financing activities | -€16.4M | -€535.4M |
| Dividends paid | €100.0K | €150.0K |
| Proceeds from borrowings | €368.1M | €309.4M |
| Repayments of borrowings | €141.7M | €1.07B |
| Lease liability payments | €10.6M | €10.3M |
| Net change in cash | €256.4M | -€292.4M |
| Balance sheet | ||
| Total assets | €4.61B | €4.98B |
| Non-current assets | €2.98B | €3.37B |
| Property, plant & equipment | €2.49B | €2.87B |
| Right-of-use assets | €124.6M | €139.3M |
| Intangible assets & goodwill | €22.4M | €23.8M |
| Current assets | €1.63B | €1.61B |
| Inventories | €531.7M | €646.2M |
| Trade & other receivables | €245.3M | €318.2M |
| Cash & equivalents | €675.0M | €442.3M |
| Total equity | €1.31B | €1.65B |
| — attributable to owners | €975.8M | €1.31B |
| Non-controlling interests | €329.5M | €342.2M |
| Non-current liabilities | €2.11B | €2.24B |
| Current liabilities | €1.20B | €1.09B |
| Trade & other payables | €323.6M | €386.4M |
| Deferred tax liabilities | €55.2M | €74.6M |
| Derived metrics | ||
| Free cash flow | €278.7M | €241.3M |
| Operating margin | 0.7% | 3.3% |
| Net margin | -5.2% | -5.2% |
| Return on equity | -10.4% | -8.4% |
| Cash conversion ratio | -3.10× | -2.86× |
| Capex coverage | 2.98× | 2.57× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€73.9M | €39.6M |
| Adjustments For Decrease Increase In Trade Account Receivable | -€39.0M | €10.7M |
| Adjustments For Depreciation and Amortisation Expense | -€397.1M | -€308.8M |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | €24.0M | €32.2M |
| Adjustments For Increase Decrease In Trade Account Payable | €33.5M | -€68.4M |
| Amount Removed From Reserve of Cash Flow Hedges and Included In Initial Cost Or Other Carrying Amount of Nonfinancial Asset Liability Or Firm Commitment For Which Fair Value Hedge Accounting Is Applied | €4.7M | €3.0M |
| Capital Reserve | €417.7M | €513.5M |
| Comprehensive Income Attributable To Noncontrolling Interests | €366.0K | €4.7M |
| Current Financial Liabilities | €502.1M | €279.4M |
| Current Government Grants | €64.3M | €83.5M |
| Current Investments | €6.5M | €11.3M |
| Current Provisions | €33.9M | €28.5M |
| Current Tax Assets Current | €8.7M | €2.7M |
| Current Tax Assets Noncurrent | €5.1M | €16.9M |
| Current Tax Liabilities Current | €13.7M | €16.0M |
| Deferred Tax Assets | €2.9M | €4.3M |
| Dividends Received Classified As Investing Activities | €55.0K | €3.4M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €23.7M | €9.1M |
| Equity and Liabilities | €4.61B | €4.98B |
| Gains Losses On Cash Flow Hedges Before Tax | €26.6M | -€18.0M |
| Gains Losses On Exchange Differences On Translation Before Tax | -€124.8M | €58.0M |
| Gains Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income Before Tax | €687.0K | -€334.0K |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €4.4M | -€13.5M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | €1.6M | €9.4M |
| Income Taxes Paid Refund Classified As Operating Activities | -€26.7M | -€77.0M |
| Increase Decrease In Working Capital | -€29.7M | €143.4M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | €0 | — |
| Increase Decrease Through Other Contributions By Owners | €0 | €34.9M |
| Increase Decrease Through Transfers and Other Changes Equity | -€54.9M | €18.5M |
| Interest Paid Classified As Financing Activities | €134.5M | €118.9M |
| Interest Received Classified As Investing Activities | €13.7M | €24.5M |
| Investment Accounted For Using Equity Method | €38.0M | €25.0M |
| Issued Capital | €40.1M | €40.1M |
| Noncurrent Biological Assets | €176.6M | €192.2M |
| Noncurrent Financial Liabilities | €1.67B | €1.83B |
| Noncurrent Government Grants | €10.9M | €12.1M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | €62.4M | €37.1M |
| Noncurrent Provisions | €69.5M | €83.0M |
| Other Adjustments To Reconcile Profit Loss | -€16.3M | -€84.9M |
| Other Comprehensive Income | -€112.2M | €20.6M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €1.8M | -€2.8M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€113.1M | €33.2M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €966.0K | -€12.5M |
| Other Current Financial Assets | €33.9M | €26.8M |
| Other Current Financial Liabilities | €181.1M | €161.1M |
| Other Current Nonfinancial Assets | €132.8M | €161.0M |
| Other Current Nonfinancial Liabilities | €80.0M | €130.8M |
| Other Expense By Function | €17.9M | €4.9M |
| Other Finance Income Cost | -€703.0K | €33.8M |
| Other Noncurrent Financial Assets | €1.1M | €1.4M |
| Other Noncurrent Financial Liabilities | €12.2M | €5.3M |
| Other Noncurrent Nonfinancial Assets | €54.8M | €57.4M |
| Other Noncurrent Nonfinancial Liabilities | €4.4M | €4.5M |
| Other Reserves | -€38.8M | €42.3M |
| Proceeds From Changes In Ownership Interests In Subsidiaries | €0 | €34.9M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €356.0K | €880.0K |
| Proceeds From Government Grants Classified As Investing Activities | €301.0K | €2.4M |
| Proceeds From Issue of Bonds Notes and Debentures | €0 | €581.8M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €141.1M | €153.8M |
| Reclassification Adjustments On Cash Flow Hedges Before Tax | €10.8M | €17.7M |
| Reclassification Adjustments On Exchange Differences On Translation Net of Tax | €0 | €0 |
| Repayments of Bonds Notes and Debentures | €68.5M | €236.4M |
| Research and Development Expense | €29.1M | €29.2M |
| Retained Earnings | €70.5M | €217.4M |
| Share of Other Comprehensive Income of Associates and Joint Ventures Accounted For Using Equity Method That Will Be Reclassified To Profit Or Loss Net of Tax | €232.0K | -€2.7M |
| Share of Other Comprehensive Income of Associates and Joint Ventures Accounted For Using Equity Method That Will Not Be Reclassified To Profit Or Loss Net of Tax | €106.0K | -€36.0K |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -€3.4M | €0 |
Methodology
Every line item above is a fact tagged in LENZING AG's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.